CureVac (NASDAQ:CVAC)

BRIEF

published on 09/13/2024 at 14:02, 2 months 9 days ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 2 months 9 days ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 2 months 10 days ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 2 months 10 days ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 2 months 13 days ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 2 months 13 days ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress
BRIEF

published on 08/15/2024 at 13:11, 3 months 7 days ago

CureVac Reports Second Quarter and First Half 2024 Financial Results and Business Developments

Financial Results Oncology CureVac MRNA Platform GSK Partnership
BRIEF

published on 08/15/2024 at 13:08, 3 months 7 days ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study

Clinical Study CureVac MRNA Vaccine Glioblastoma CVGBM
PRESS RELEASE

published on 08/15/2024 at 13:06, 3 months 7 days ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
CureVac announces Q2 2024 financial results, new agreement with GSK, strategic workforce reduction, milestone payment, board appointments, CFO transition, and cash position update

Financial Results Business Update Q2 2024 CureVac GSK Agreement
BRIEF

published on 08/15/2024 at 13:05, 3 months 7 days ago

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Supervisory Board Oncology MRNA Technology CureVac Dr. Mehdi Shahidi

Published on 11/22/2024 at 23:55, 10 hours 32 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 10 hours 57 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 11 hours 22 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 11 hours 22 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 11 hours 57 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 16 hours 12 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 16 hours 27 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 16 hours 33 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 17 hours 31 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 18 hours 27 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 19 hours 52 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 15 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 16 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 16 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News